[ISSUES OF ROUTING PATIENTS WITH AUTOIMMUNE HEPATITIS].

Autoimmune hepatitis is a chronic, immune-mediated liver disease characterized by an increased level of immunoglobulins G and/or gamma globulins, the presence of autoantibodies and a typical histological picture. Diagnosis of autoimmune hepatitis causes difficulties due to various variants of the course, wide variability of the clinical picture, which leads to a large number of missed cases of the disease. Treatment of аutoimmune hepatitis is aimed at reducing the activity of an inadequate response of the immune system against cells of its own body and achieving complete remission of the disease.

[Assessment of the possible impact of hepatitis viruses on the development and course of autoimmune liver diseases].

Background: Despite the well-studied pathogenesis, the etiology of autoimmune liver disease (AILD) remains unknown.

Aim: To determine the significance of hepatitis A, B, C and E viruses in the development and progression of AILD.

Materials And Methods: A single-center case-control study included 139 patients with AILD: autoimmune hepatitis - AIH (=46), primary biliary cholangitis - PBS (=74), primary sclerosing cholangitis - PSC (=19).

[Non-alcoholic fatty liver disease and type 2 diabetes mellitus: issues of the liver fibrosis diagnostics].

Aim: To evaluate the frequency of liver fibrosis progression to stage 34 among patients with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes and obesity, to identify predictors of severe liver fibrosis, to propose an algorithm for diagnosing fibrosis in this category of patients.

Materials And Methods: 160 patients with NAFLD, type 2 diabetes mellitus (DM) and obesity and 50 patients with NAFLD without diabetes were comprehensively examined. Patients underwent laboratory examination (clinical blood test, biochemical analysis, immunoglobulins G, M, autoantibody assay, coagulogram), liver ultrasound.

[Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis].

Today, there is no complete clarity about the pathogenetic mechanisms of the hepatic decompensation in patients with HCV-cirrhosis during the course of direct-acting antiviral (DAAs) therapy. The current article describes several clinical observations of decompensation (with the development of liver failure and portal hypertension) in cirrhotic patients during the course of DAAs-therapy of hepatitis C. The authors present contemporary views and their own assumptions about the possible mechanisms of the hepatic decompensation associated with DAAs-therapy in patients with liver cirrhosis.

[Treatment of patients with HBV cirrhosis: successes, unsolved problems].

Annually 0.5-1 million people die from terminal liver injuries or hepatocellular carcinoma, which are associated with hepatitis B virus (HBV); 5-10% of liver transplantations are performed due to the outcomes of HBV infections. All patients with liver cirrhosis in the outcome of replication-phase chronic hepatitis B need antiviral therapy.